Becton Dickinson (BDX) AI Stock Analysis
Becton Dickinson
(BMV:BDX)
No summary available
Becton Dickinson (BDX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- MXN 53.90B
- Dividend Yield
- 1.65%
- Average Volume (3M)
- 12
- Price to Earnings (P/E)
- 59.6
- Beta (1Y)
- 0.15
- Revenue Growth
- -11.05%
- EPS Growth
- -44.33%
- Country
- Mexico
- Employees
- 72,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Becton Dickinson Business Overview & Revenue Model
Company Description
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, a...
Becton Dickinson Earnings Call Summary
The call conveyed strong execution across BD's focused med‑tech portfolio: revenue and adjusted EPS beat expectations, growth platforms showed double-digit expansion, productivity and cash flow improved materially, and the company raised EPS guidance. Headwinds are defined and manageable — chiefly Alaris remediation, tariffs, vaccine weakness in China and some margin pressure versus the prior year — and management laid out clear mitigation actions (pricing, productivity, commercial investments, AI for supply chain). Overall the positives materially outweigh the negatives.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
BD updated fiscal '26 guidance, saying revenue is now expected toward the high end of its low single‑digit FX‑neutral range (currency now a ~100 bp tailwind at current spot rates) and raising the midpoint of adjusted EPS guidance to a range of $12.62–$12.72; the company still expects adjusted operating margin of about 25% (inclusive of tariffs) and an adjusted effective tax rate of 16–17%. Management cited Q3 results of $5.0B revenue (up 4.4%), adjusted gross margin of 54.3%, adjusted operating margin of 24.9% and adjusted EPS of $3.23 as the basis for the update, noted tariffs trimmed margins by roughly 110 bps, and highlighted YTD free cash flow of $1.7B (up 45%) and $3.1B returned to shareholders ($2.3B repurchases, $0.9B dividends) with net leverage ~2.9x (2.5x target). Looking to FY‑27, management reiterated a low single‑digit revenue starting point with a defined ~200 bp Alaris headwind next year and said it expects only “modest” EPS leverage off that baseline, with pricing, BD Excellence productivity and favorable mix helping to offset headwinds and a longer‑term free cash flow conversion goal of ~90%.
Becton Dickinson Risk Analysis
Becton Dickinson disclosed 25 risk factors in its most recent earnings report. Becton Dickinson reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksBecton Dickinson Peers Comparison
Overall Rating
WST78Outperform
MDLN69Neutral
ICUI65Neutral
TFX55Neutral
BAX45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $28.74B | 46.00 | 21.08% | 0.21% | 12.60% | 32.05% | |
| 69Neutral | $42.23B | 37.35 | 5.45% | ― | 12.12% | -46.11% | |
| 65Neutral | $4.10B | 136.48 | 1.41% | ― | -8.84% | ― | |
| 55Neutral | $5.92B | -6.00 | -31.83% | 0.97% | -14.49% | -644.98% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $11.90B | -16.67 | -11.62% | 0.17% | 5.33% | -164.67% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MX:BDX | Becton, Dickinson and Co | 3610.00 | 1009.98 | 38.85% | |
| BAX | Baxter International Inc | 23.00 | 5.09 | 28.46% | |
| ICUI | ICU Medical | 163.78 | 38.12 | 30.34% | |
| TFX | Teleflex | 139.77 | 16.73 | 13.60% | |
| WST | West Pharmaceutical Services, Inc. | 412.62 | 126.57 | 44.25% | |
| MDLN | Medline, Inc. Class A | 32.12 | -8.88 | -21.66% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.